Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Molecular biology reports - 1 Sept 2012

Karkucak Mutlu, Yakut Tahsin, Ozkocaman Vildan, Ozkalemkas Fahir, Ali Ridvan, Bayram Murat, Gorukmez Orhan, Ocakoglu Gokhan

Abstract excerpt

An activating mutation of Janus kinase 2 (JAK2-V617F) was previously described in chronic myeloproliferative disorders (MPD). In previously published studies, the frequency of the JAK2-V617F mutation was determined to be 80-90 % for patients with polycythemia vera (PV) and 40-70 % for essential thrombocythemia (ET). In this study, we analyzed the relationship between the JAK2-V617F mutation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation Rate

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Turkey

Source

Identifiers

PMID: 22722988
DOI: 10.1007/s11033-012-1721-x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.PMID 22722988Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.Semantic proximity Read ↗

Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Frequency of Janus associated kinase 2 (V617F) mutation in patients of polycythemia vera.Semantic proximity Read ↗

Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.Semantic proximity Read ↗

Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Semantic proximity Read ↗

Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.Semantic proximity Read ↗

[JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].Semantic proximity Read ↗

Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.Semantic proximity Read ↗

Myeloproliferative neoplasms and JAK2 mutations.Semantic proximity Read ↗

JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.Semantic proximity Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.